Page 23 - Cipla

Cipla's Q2 profit before tax grows 34% on Indian business revival

Co undertook a distribution network restructuring exercise in the last few months

Cipla acquires anti-infective drug Elores from Venus Remedies

Elores is used to treat life threatening infections

Cipla looks at digital media for expanding footprint and reach customers

The pharma major looks to expand its footprint by driving up the diagnosis around diseases, uses digital media to take the brand directly to the end-user

Cipla rebounds 13% from 52-week low on heavy volumes

The United States Food and Drug Administration (USFDA) conducted a cGMP (current good manufacturing practices) inspection at the company's Goa manufacturing facility from September 16-27, 2019.

Cipla's unbranded drug business may take a hit in FY20, say analysts

Analysts see full recovery by Q3 as company revamps distribution network

Goa facility issue worsens Cipla's growth worries; stock falls over 3%

India business has been soft given the realignment of the sales channel

Cipla shareholders approve proposal to raise up to Rs 3,000 crore

In a regulatory filing, Cipla said 99.68% shareholders polled in favour of the resolution to raise funds

Declining India business pulls down Cipla's Q1 growth; US sales grow

Profitability though got a boost with higher contribution from limited competition products in the US

Cipla increases stake in consumer health biz to 100%, looks for tie-ups

The drug maker had set up a separate company with private equity investment in FY2016 to tap the fast growing over the counter medicine portfolio

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

Cipla urges govt to increase funds, ease policies for domestic pharma firms

In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health

InvaGen Pharma gets USFDA approval for neuropathic pain management drug

Cipla said the approved product is a generic therapeutic equivalent version of Pfizer's Lyrica

Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright

The JV will set up a manufacturing facility of respiratory products; the plant is expected to be commissioned in 2020

Looking at continued growth across key markets in FY20, says Cipla

Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year

Street cautious on Cipla despite healthy March quarter numbers

Higher competitive intensity, increasing investments, and moderate growth could weigh on returns

US court denies Amgen's request for preliminary injunction against Cipla

Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order

Margin gain remains a key trigger for Cipla, say analysts

Despite strong domestic growth and improving US prospects, analysts remain sceptical on improvement in profitability in the near-term

Cipla campaign hard-hitting; was aimed at opening people's eyes: Lav Dhruv

We launched the campaign with hoardings showing stark shots of the most polluted places in Delhi, along with a simple message, urging the audience to act quickly before it's too late

Cipla recalls 4,800 bottles of anti-HIV tablets from American market

As per the latest Enforcement Report by the USFDA, the reason for the recall of the bottles is 'failed dissolution specifications'